AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study suggests carboplatin could be first-line chemotherapy.(for the treatment of ovarian cancer)
2002 SEP 12 - (NewsRx.com & NewsRx.net) -- Results of an international study in the August 17, 2002, issue of the Lancet suggest that the drug carboplatin could become a first-line chemotherapeutic agent for the treatment of ovarian cancer. Carboplatin was found to be less toxic although it had no overall survival benefit, compared with other drugs assessed in the study.
Ovarian cancer is the sixth most common cancer of women worldwide; around 165,000 people are diagnosed with the disease every year, and 5-year survival for women with advanced disease is only around 30%. Treatment involves surgery (i.e., total hysterectomy or removal of the ovaries) and postoperative chemotherapy.
Previous research has shown that both combinations of the chemotherapeutic drugs cyclophosphamide, doxorubicin, and cisplatin (known as CAP) and use of carboplatin produce similar survival and progression-free survival rates.
More recently, the taxane paclitaxel combined with carboplatin has become a widely accepted treatment for the disease. The International Collaborative Ovarian Neoplasm (ICON) Collaborators, led by Peter Harper, consultant medical oncologist at Guy's Hospital in London, and Nicoletta Colombo, associate professor in obstetrics and gynaecology at the European Institute of Oncology in Milan, Italy, aimed to compare the safety and efficacy of paclitaxel plus carboplatin with a control of either CAP or carboplatin alone. The trial was coordinated by the MRC Clinical Trials Unit, London, U.K.
Women with ovarian cancer (n=2074) from 130 centers in eight countries were randomly assigned paclitaxel plus carboplatin or control, the control (CAP or single-agent carboplatin) being chosen ...
- Paclitaxel Plus Cisplatin: Better Ovarian Ca Survival.
- Magazine article from: OB GYN News MOON, MARY ANN September 1, 2000 700+ words
...standard therapy for advanced ovarian cancer, now that two large, phase...women with advanced epithelial ovarian cancer to see if they could confirm...The global response rate with paclitaxel plus cisplatin (78%) also was...
- Paclitaxel plus vinorelbine are moderately effective in advanced breast cancer.
- Newspaper article from: Biotech Business Week April 12, 2004 700+ words
...III trial studied the efficacy and toxicity of full dose paclitaxel plus vinorelbine, as salvage chemotherapy in patients with metastatic...their research in the Journal of Chemotherapy (Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant...
- Gynecologic oncology: S-P's Caelyx in platinum-sensitive ovarian...
- Newspaper article from: Pharma Marketletter March 6, 2006 700+ words
...sensitive recurrent ovarian cancer were discussed at...challenges in recurrent ovarian cancer," organized by...therapy with standard paclitaxel plus carboplatin combination...platinum-sensitive ovarian cancer. The expectation...
- InterMune Announces Start of Phase III Clinical Trial Of Actimmune for the...
- Press release article from: PR Newswire February 5, 2002 700+ words
...survival rate for ovarian cancer since the advent...adjunct to paclitaxel plus carboplatin...stage 3 or 4 ovarian cancer." Ovarian...adjunct to paclitaxel plus carboplatin...previously untreated ovarian cancer; and Actimmune...
- Platinum-paclitaxel as second-line chemotherapy for relapsed ovarian...
- Newspaper article from: Clinical Oncology Alert August 1, 2003 700+ words
...treatment of ovarian cancer. In the current...regimens) or paclitaxel plus platinum...in favor of paclitaxel plus platinum...Thus, the paclitaxel plus platinum chemotherapy...sensitive ovarian cancer. * COMMENT...
- Intraperitoneal Chemotherapy for Ovarian Cancer: The QOL Trade-Off.(quality of...
- Newspaper article from: Clinical Oncology Alert Ershler, William B. March 1, 2007 700+ words
...after successful debulking of ovarian cancer.1-3 The Gynecologic Oncology...assigned to receive either IV paclitaxel plus cisplatin or IV paclitaxel plus...Patients (n = 415) with stage III ovarian cancer or primary peritoneal carcinoma...
- Marshall Edwards, Inc., Names Second Study Site in Multi-National Ovarian...
- Press release article from: PR Newswire June 14, 2004 700+ words
...chemotherapy to treat ovarian cancer.(1) This trial...monotherapy in late-stage ovarian cancer patients. Researchers...have late-stage ovarian cancer that has become refractory...paclitaxel only, (2) paclitaxel plus phenoxodiol, and...
- Ovarian cancer, a silent killer for Indonesian women: Study.
- Newspaper article from: Jakarta Post August 9, 2000 700+ words
...may be at a high risk of developing ovarian cancer. Dr. Sjahrul Sjamsuddin, a gynecologist...said the doctor during a seminar on ovarian cancer. Only a very few realize that the...talcum powder and the development of ovarian cancer in women," he said. The doctor explained...
- Ovarian cancer strikes one in 68 women: Now experts agree on a set of symptoms...
- Newspaper article from: Tulsa World (Tulsa, OK) August 2, 2007 700+ words
...estimated 15,000 Americans die of ovarian cancer, where malignant cells are found in...organs, the ovaries. For a long time, ovarian cancer was called the "silent killer" because...poor. Almost 70 percent of women with ovarian cancer are not diagnosed until the disease...
- Ovarian cancer genomic tests not reducing deaths.
- Magazine article from: Diagnostic Update October 19, 2006 700+ words
Ovarian cancer genomic tests not reducing deaths...to diagnose and guide treatment of ovarian cancer are not shown to decrease the number...125 or BRCA1 and BRCA2 to diagnose ovarian cancer or identify women at risk. Among...
Source: HighBeam Research, Study suggests carboplatin could be first-line chemotherapy.(for the...